1 / 6

Olimab 60mg injection | Denosumab 60mg |Apple pharmaceuticals

Olimab 60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors @ Apple pharmaceuticals

Emimadi
Download Presentation

Olimab 60mg injection | Denosumab 60mg |Apple pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Olimab 60mg injection | Denosumab 60mg Apple pharmaceuticals Olimab 60mg | Olimab 60mg injection | Denosumab 60mg | Denosumab 60mg tablet Olimab 60mg injection (Denosumab) Olimab 60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases. Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids. Each heavy chain contains of 448 amino acids with 4 intramolecular disulfides. PRESCRIBED Treatment for patients having postmenopausal women with osteoporosis at high risk for fracture.

  2. Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer. Treatment for patients having to increase bone mass in women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. DOSAGE For adult : Osteoporosis : 60mg SC (subcutaneously) once every 6 months Injection of drug should be done in upper arm, upper thigh or abdomen Giant Cell Tumor of bone : 120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Injection of drug should be done in upper arm, upper thigh or abdomen Osteolytic Bone Metastases of Solid Tumors : 120mg subcutaneously every 4 weeks Injection of drug should be done in upper arm, upper thigh or abdomen Hypercalcemia : Dose of 120mg Olimab tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment Injection of drug should be done in upper arm, upper thigh or abdomen Dosage and administration in pediatric : 13 years and older and 45kg or more Giant Cell Tumor of bone :

  3. Dose of 120mg Olimab tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment OVERDOSE: Olimab overdose has no overdose. If occurs seek to emergency department and call poison control MECHANISM Denosumab linked to RANKL, a protein which is specific for the formation, function and survival of osteoclasts, the cells necessary for bone resorption. Denosumab prohibits osteoclast formation, function and survival hence, reducing bone resorption and raising bone mass and strength of the bone. Peak plasma concentration: 6.75mcg/mL Tmax : 10days Without aggregation in Olimab pharmacokinetics with duration was noticed upon multiple dosing of 60 mg SC administered once every 6 months. Pharmacokinetics of Olimab will not affected by the binding antibodies formation. Half-life is 25.4 days. PRECAUTION

  4. • Before to start treatment withOlimab, discuss with the doctor about any other regimens you are using (including over-the-counter drugs, vitamins, or herbal remedies). Do not take aspirin or products containing aspirin unless your doctor permits this. •Olimab injection may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. Inform your doctor of any immuno-suppressive drugs you early consume. • Not to receive any type of vaccination without your doctor's consultation while admonishing denosumab. • Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment • DuringOlimab treatment do not breastfeed your infants. DRUG INTERACTION No formal drug-drug interaction with denosumab during trials.

  5. When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased CONTRAINDICATION Olimab is contraindicated in patients having Hypocalcemia, Pregnancy, Hypersensitivity STORAGE Store at 2℃ to 8℃ in the original container, avoid freeze Before to administration keep at room temperature Olimab protect from direct light and heat. SIDE EFFECTS Common side effects for the patient taking Olimab 60mg as follows : Fatigue, Muscle weakness, Phosphorus level reduced in blood, Nausea Less common side effects for patients taking Olimab : Dyspnea, Hypocalcemia, Cough, Arthralgia, Limb pain, Eczema, Headache MISSED DOSE

  6. Take the dose immediately before next dose duration, then left off the missed dose and continue regular schedule. Avoid taking double dose at same time. Please consult the doctor for further information. Contact Us phone No :9987711567 Email :info@myapplepharma.com website https://myapplepharma.com/olimab-60mg.php

More Related